Poseida Therapeutics, a Phase 1 biotech developing CAR T cell therapies for multiple myeloma and prostate cancer, filed on Friday with the SEC to raise up to $115 million in an initial public offering.
The San Diego, CA-based company was founded in 2014 and plans to list on the Nasdaq under the symbol PSTX. Poseida Therapeutics filed confidentially on November 1, 2018. Citi, Credit Suisse and Wells Fargo Securities are the joint bookrunners on the deal. No pricing terms were disclosed.
